These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
228 related items for PubMed ID: 19395453
1. Does mycophenolate mofetil prevent extra-renal flares in systemic lupus erythematosus? Results from an observational study of patients in a single practice treated for up to 5 years. Posalski JD, Ishimori Ml, Wallace DJ, Weisman MH. Lupus; 2009 May; 18(6):516-21. PubMed ID: 19395453 [Abstract] [Full Text] [Related]
2. Mycophenolate mofetil is effective in reducing disease flares in systemic lupus erythematosus patients: a retrospective study. Nannini C, Crowson CS, Matteson EL, Moder KG. Lupus; 2009 Apr; 18(5):394-9. PubMed ID: 19318390 [Abstract] [Full Text] [Related]
3. Mycophenolate mofetil in the treatment of SLE and systemic vasculitis: experience at a single university center. Lourdudoss C, Vollenhoven Rv. Lupus; 2014 Mar; 23(3):299-304. PubMed ID: 24399811 [Abstract] [Full Text] [Related]
4. Mycophenolate mofetil in systemic lupus erythematosus: results from a retrospective study in a large monocentric cohort and review of the literature. Conti F, Ceccarelli F, Perricone C, Massaro L, Cipriano E, Pacucci VA, Truglia S, Miranda F, Morello F, Alessandri C, Spinelli FR, Valesini G. Immunol Res; 2014 Dec; 60(2-3):270-6. PubMed ID: 25468307 [Abstract] [Full Text] [Related]
5. Experience with mycophenolate mofetil as maintenance therapy in five pediatric patients with severe systemic lupus erythematosus. Dittrich K, Ross S, Benz K, Amann K, Dötsch J. Klin Padiatr; 2009 Dec; 221(7):425-9. PubMed ID: 20013565 [Abstract] [Full Text] [Related]
6. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials. Petri MA, van Vollenhoven RF, Buyon J, Levy RA, Navarra SV, Cervera R, Zhong ZJ, Freimuth WW, BLISS-52 and BLISS-76 Study Groups. Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628 [Abstract] [Full Text] [Related]
7. Mycophenolate mofetil as maintenance therapy for childhood-onset systemic lupus erythematosus patients with severe lupus nephritis. Kizawa T, Nozawa T, Kikuchi M, Nagahama K, Okudela K, Miyamae T, Imagawa T, Nakamura T, Mori M, Yokota S, Tsutsumi H. Mod Rheumatol; 2015 Mar; 25(2):210-4. PubMed ID: 25159157 [Abstract] [Full Text] [Related]
8. Tolerability of mycophenolate mofetil in patients with systemic lupus erythematosus. Riskalla MM, Somers EC, Fatica RA, McCune WJ. J Rheumatol; 2003 Jul; 30(7):1508-12. PubMed ID: 12858449 [Abstract] [Full Text] [Related]
9. Mycophenolate mofetil in the treatment of systemic lupus erythematosus. Dall'Era M. Curr Opin Rheumatol; 2011 Sep; 23(5):454-8. PubMed ID: 21720247 [Abstract] [Full Text] [Related]
10. [Manifestation of diffuse proliferative lupus nephritis in a patient treated with long-term mycophenolate mofetil]. Sixdorf U, Bauer H, Märker-Hermann E. Dtsch Med Wochenschr; 2006 Oct 13; 131(41):2266-9. PubMed ID: 17036267 [Abstract] [Full Text] [Related]
12. Mycophenolate mofetil for non-renal manifestations of systemic lupus erythematosus: a systematic review. Mok CC. Scand J Rheumatol; 2007 Oct 13; 36(5):329-37. PubMed ID: 17963161 [Abstract] [Full Text] [Related]
13. Mycophenolate Mofetil and New-Onset Systemic Lupus Erythematosus: A Randomized Clinical Trial. You Y, Zhou Z, Wang F, Li J, Liu H, Cheng X, Su Y, Chen X, Zheng H, Sun Y, Shi H, Hu Q, Xu J, Teng J, Yang C, Ye J. JAMA Netw Open; 2024 Sep 03; 7(9):e2432131. PubMed ID: 39283640 [Abstract] [Full Text] [Related]
14. Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil. Zahr N, Arnaud L, Marquet P, Haroche J, Costedoat-Chalumeau N, Hulot JS, Funck-Brentano C, Piette JC, Amoura Z. Arthritis Rheum; 2010 Jul 03; 62(7):2047-54. PubMed ID: 20506558 [Abstract] [Full Text] [Related]
15. Mycophenolate mofetil and systemic lupus erythematosus: an overview. Pisoni CN, Karim Y, Cuadrado MJ. Lupus; 2005 Jul 03; 14 Suppl 1():s9-11. PubMed ID: 15803925 [Abstract] [Full Text] [Related]
16. Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort. Lopez R, Davidson JE, Beeby MD, Egger PJ, Isenberg DA. Rheumatology (Oxford); 2012 Mar 03; 51(3):491-8. PubMed ID: 22109798 [Abstract] [Full Text] [Related]
17. Mycophenolate Mofetil in Nonrenal Manifestations of Systemic Lupus Erythematosus: An Observational Cohort Study. Tselios K, Gladman DD, Su J, Urowitz MB. J Rheumatol; 2016 Mar 03; 43(3):552-8. PubMed ID: 26773121 [Abstract] [Full Text] [Related]
18. Mycophenolate mofetil for remission induction in severe lupus nephritis. Cross J, Dwomoa A, Andrews P, Burns A, Gordon C, Main J, Mathieson P, O'Donoghue D, Jayne D, Renal Association Clinical Trials Subcommittee. Nephron Clin Pract; 2005 Mar 03; 100(3):c92-100. PubMed ID: 15824513 [Abstract] [Full Text] [Related]
19. Differential effects of cyclophosphamide and mycophenolate mofetil on cellular and serological parameters in patients with systemic lupus erythematosus. Fassbinder T, Saunders U, Mickholz E, Jung E, Becker H, Schlüter B, Jacobi AM. Arthritis Res Ther; 2015 Apr 03; 17(1):92. PubMed ID: 25890338 [Abstract] [Full Text] [Related]
20. Open label randomized controlled trial assessing the efficacy of mycophenolate sodium against other conventional immunosuppressive agents in active systemic lupus erythematosus patients without renal involvement. Yahya F, Jasmin R, Ng CT, Cheah TE, Sockalingam S. Int J Rheum Dis; 2013 Dec 03; 16(6):724-30. PubMed ID: 24119227 [Abstract] [Full Text] [Related] Page: [Next] [New Search]